Sitemap > News > Technology
Displaying 1 - 50 of 2684 results
- Human Genome Sciences and GlaxoSmithKline Initiate Second Phase 3 Clinical Trial of LymphoStat-B® in Systemic Lupus Erythematosus
- Progenics and Wyeth Announce FDA Has Accepted for Filing the New Drug Application for Subcutaneous Methylnaltrexone
- Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
- Celsion Completes Enrollment In Phase I Liver Cancer Study
- Data Show Improved Response Rate when Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
- Epeius Biotechnologies Gains Fda Approval For Two New Clinical Trials Using Rexin-G (Tm) For Breast Cancer And Sarcoma
- Xeloda® Plus Avastin® Combination Delays Disease Progression in Women with Advanced Breast Cancer
- CAELYX(R) Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
- Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
- CytImmune Presents Positive CYT-6091 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
- IDM Pharma Presents Interim Phase II Data From EP-2101 Lung Cancer Vaccine Clinical Trial
- Introgen Reports Updated Phase 2 ADVEXIN(R) Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
- Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer
- Oxford BioMedica and Sanofi-Aventis Report Encouraging New Trovax® Phase II Trial Results in Renal Cancer
- Final Data from a Phase 2 Trial Presented at ASCO Specifies Dose-dependent Activity of Adecatumumab (MT201)
- Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
- Cell Genesys and Medarex Report Follow-Up Data From a Phase 1 Combination Therapy Trial With GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody
- RESULTS OF VEGF TRAP (AFLIBERCEPT) HIGHLIGHTED AT ASCO 2007 ANNUAL MEETING
- OXFORD BIOMEDICA AND SANOFI-AVENTIS REPORT NEW TROVAX® PHASE II TRIAL RESULTS IN RENAL CANCER
- Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
- Patients Who Took Investigational Melanoma Compound CP-675,206 Showed Favorable Survival Outcomes, Pfizer Says
- ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer
- Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer.
- ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
- Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
- Antigenics’ QS-21 Stimulon Adjuvant Enters Phase 3 Clinical Trial of GlaxoSmithKline’s Novel Cancer Immunotherapeutic in Non-Small Cell Lung Cancer
- Biovest to File for Accelerated Conditional Approval of BiovaxID
- Cervarix, the GSK cervical cancer candidate vaccine, provides sustained immune response in 100 per cent of women up to 55 years of age
- Genta Announces Results of Phase 1 Study using Genasense Administered by Intermittent Subcutaneous Injection
- Encouraging clinical activity of GSK’s novel cancer immunotherapeutic confirmed in phase II study in patients with most common form of lung cancer
- Human Genome Sciences Announces Positive Final Results of Phase 2b Trial of Albuferon
- IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
- IMMUNOMEDICS REPORTS INITIAL CLINICAL RESULTS WITH hPAM4 FOR PANCREATIC CANCER THERAPY
- Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial
- ROXRO PHARMA’s novel intranasal pain reliever effective, well tolerated in phase 3 study
- XTL PROVIDES UPDATE ON PHASE I CLINICAL TRIAL OF XTL-2125
- YM BIOSCIENCES CLEARED TO INITIATE CLINICAL TRIAL OF NIMOTUZUMAB IN COLORECTAL CANCER
- Aspreva Announces Fast-Track Designation Granted by the FDA for CellCept in Lupus Nephritis
- Regeneron Submits Biologics License Application To U.S. FDA For IL-1 TRAP (RILONACEPT) For Treatment Of CAPS
- Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
- Pivotal phase III trial showed RevoladeTM (eltrombopag) raised platelet counts and reduced bleeding in patients with chronic ITP
- Abbott's HUMIRA (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
- Phase III clinical trial with 4-month long-acting formulation of triptorelin: Ipsen decides not to perform further administration
- FDA Accepts and Grants Priority Review of Erbitux (Cetuximab) sBLA for Overall Survival in Patients With Advanced Colorectal Cancer
- Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
- KaloBios Initiates a U.S. Phase 1 Study of Its Second Drug Candidate, KB001
- CEL-SCI Receives US FDA Orphan Drug Designation for Its Cancer Drug Multikine
- Interim Analysis of Anti-Cancer Vaccine, BiovaxID, to be Conducted
- Human Genome Sciences Reports that a Phase 2 Study of Lymphostat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
- LCT successfully transplants first diabetes patient